Latest Clinical Data: RADIANCE-HTN SOLO Trial Crossover Results

Ajay J. Kirtane presents the results of the RADIANCE-HTN SOLO late-breaking trial.

The RADIANCE-HTN SOLO trial previously reported statistically significant drops in BP at 2M (blinded/“off meds”) and 6M (blinded/on “titrated meds”) with strong safety profiles. After 12M, the subjects in the sham group were able to crossover to receive renal denervation. The crossover results are consistent with the previous SOLO results and provide additional evidence that Paradise renal denervation may be effective in lowering BP. The crossover data provides valuable insight into the performance of the Paradise Renal Denervation System when patients are unblinded and on standard of care medications.